Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

NADOLOL AND BENDROFLUMETHIAZIDE

BENDROFLUMETHIAZIDE; NADOLOL

Standard Dose
5MG;40MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview NADOLOL AND BENDROFLUMETHIAZIDE is listed in Drugs@FDA under application 078688 (ANDA).

Marketing status: Discontinued Active ingredient BENDROFLUMETHIAZIDE; NADOLOL Form and strength TABLET;ORAL - 5MG;40MG Sponsor NATCO PHARMA Submission history Latest submission status date: 2008-02-15 00:00:00.

Structured Monograph

Clinical summary

Approval overview NADOLOL AND BENDROFLUMETHIAZIDE is listed in Drugs@FDA under application 078688 (ANDA). Marketing status: Discontinued Active ingredient BENDROFLUMETHIAZIDE; NADOLOL Form and strength TABLET;ORAL - 5MG;40MG Sponsor NATCO PHARMA Submission history Latest submission status date: 2008-02-15 00:00:00. Submission type: ORIG.

Monitoring

  • • Review priority: STANDARD
  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.
NADOLOL AND BENDROFLUMETHIAZIDE (BENDROFLUMETHIAZIDE; NADOLOL) | Drug Monograph | MedicHelpline